These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. Brancaccio D, Gallieni M, Niwa T, Braidotti P, Coggi G. J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976 [Abstract] [Full Text] [Related]
7. Beta2-microglobulin-selective adsorbent column (Lixelle) for the treatment of dialysis-related amyloidosis. Suzuki K, Shimazaki M, Kutsuki H. Ther Apher Dial; 2003 Feb; 7(1):104-7. PubMed ID: 12921124 [Abstract] [Full Text] [Related]
8. Long-term efficacy and safety of the small-sized β2-microglobulin adsorption column for dialysis-related amyloidosis. Yamamoto Y, Hirawa N, Yamaguchi S, Ogawa N, Takeda H, Shibuya K, Kawahara K, Kojima H, Dobashi Y, Fujita M, Azusima K, Miyazaki N, Kobayashi M, Kobayashi C, Fujiwara A, Yuto J, Saka S, Yatsu K, Toya Y, Yasuda G, Ohnishi T, Umemura S. Ther Apher Dial; 2011 Oct; 15(5):466-74. PubMed ID: 21974700 [Abstract] [Full Text] [Related]
9. Historical background and clinical treatment of dialysis-related amyloidosis. Yamamoto S, Gejyo F. Biochim Biophys Acta; 2005 Nov 10; 1753(1):4-10. PubMed ID: 16226497 [Abstract] [Full Text] [Related]
10. Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis. Yamamoto S, Yamamoto K, Hirao Y, Yamaguchi K, Nakajima K, Sato M, Kawachi M, Domon M, Goto K, Omori K, Iino N, Shimada H, Aoyagi R, Ei I, Goto S, Goto Y, Gejyo F, Yamamoto T, Narita I. Amyloid; 2024 Jun 10; 31(2):105-115. PubMed ID: 38343068 [Abstract] [Full Text] [Related]
11. Beta2-microglobulin and renal bone disease. Wada T, Miyata T, Sakai H, Kurokawa K. Perit Dial Int; 1999 Jun 10; 19 Suppl 2():S413-6. PubMed ID: 10406556 [Abstract] [Full Text] [Related]
12. Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis. Jimenez RE, Price DA, Pinkus GS, Owen WF, Lazarus JM, Kay J, Turner JR. Am J Surg Pathol; 1998 Jun 10; 22(6):729-35. PubMed ID: 9630180 [Abstract] [Full Text] [Related]
13. Cartilage biomarkers in hemodialysis patients and the effect of beta2-microglobulin on articular chondrocytes. Sunk IG, Demetriou D, Szendroedi J, Amoyo L, Raffetseder A, Hörl WH, Sunder-Plassmann G, Smolen JS, Bobacz K. Osteoarthritis Cartilage; 2008 Nov 10; 16(11):1336-42. PubMed ID: 18457963 [Abstract] [Full Text] [Related]
14. Pathogenesis and management of dialysis-related amyloid bone disease. Nangaku M, Miyata T, Kurokawa K. Am J Med Sci; 1999 Jun 10; 317(6):410-5. PubMed ID: 10372842 [Abstract] [Full Text] [Related]
16. Dialysis-related amyloidosis of the heart in long-term hemodialysis patients. Takayama F, Miyazaki S, Morita T, Hirasawa Y, Niwa T. Kidney Int Suppl; 2001 Feb 10; 78():S172-6. PubMed ID: 11169005 [Abstract] [Full Text] [Related]
18. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miyata T, Inagi R, Kurokawa K. Miner Electrolyte Metab; 1999 Feb 10; 25(1-2):114-7. PubMed ID: 10207272 [Abstract] [Full Text] [Related]
19. Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Giorgetti S, Stoppini M, Tennent GA, Relini A, Marchese L, Raimondi S, Monti M, Marini S, Østergaard O, Heegaard NH, Pucci P, Esposito G, Merlini G, Bellotti V. Protein Sci; 2007 Feb 10; 16(2):343-9. PubMed ID: 17242436 [Abstract] [Full Text] [Related]
20. Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin. Gejyo F, Suzuki S, Arakawa M. Ther Apher; 1997 May 10; 1(2):126-8. PubMed ID: 10225756 [Abstract] [Full Text] [Related] Page: [Next] [New Search]